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Abstract
Background: The elderly are predisposed to chronic osteomyelitis because of the immunocompromised nature of
aging and increasing number of chronic comorbidities. Chronic osteomyelitis may significantly affect the health of
the elderly; however, its impact on long-term mortality remains unclear. We conceived this retrospective
nationwide population-based cohort study to address this issue.
Methods: We identified 10,615 elderly patients (≥65 years) comprising 965 patients with chronic osteomyelitis and
9650 without chronic osteomyelitis matched at a ratio of 1:10 by age and gender between 1999 and 2010 from the
Taiwan National Health Insurance Research Database. The risk of chronic osteomyelitis between the two cohorts
was compared by a following-up until 2011.
Results: Patients with chronic osteomyelitis had a significantly higher mortality risk than those without chronic
osteomyelitis [incidence rate ratio (IRR): 2.29; 95 % confidence interval (CI): 2.01–2.59], particularly the old elderly
(≥85 years; IRR: 3.27; 95 % CI: 2.22–4.82) and males (IRR: 2.7; 95 % CI: 2.31–3.16). The highest mortality risk was
observed in the first month (IRR: 5.01; 95 % CI: 2.02–12.42), and it remained persistently higher even after 6 years
(IRR: 1.53; 95 % CI: 1.13–2.06) of follow-up. Cox proportional hazard regression analysis showed that chronic
osteomyelitis [adjusted hazard ratio (AHR): 1.89; 95 % CI: 1.66–2.15], advanced age (≥85 years; AHR: 2.02; 95 % CI:
1.70–2.41), male (AHR: 1.34; 95 % CI: 1.22–1.48), and chronic comorbidities were independent predictors of mortality.
Conclusions: This study demonstrated that chronic osteomyelitis significantly increased the long-term mortality risk
in the elderly. Therefore, strategies for prevention and treatment of chronic osteomyelitis and concomitant control
of chronic comorbidities are very important for the management of the elderly, particularly for a future with an
increasingly aged population worldwide.
Keywords: Chronic osteomyelitis, Elderly, Long-term mortality
Background
The proportion of elderly individuals (≥65 years old)
comprised 6.2 % of the world population in 1992, which
is expected to rise to 20 % by 2050 [1]. By 2030, 20 % of
the U.S. population is estimated to be more than 65 years
old [2]. In Taiwan, owing to a decrease in the fertility
rate, medical advances, and a comprehensive national
healthcare system, the proportion of elderly individuals
increased from 7 % in 1993 to 11.33 % in 2013 [3]. This
steady increase in the elderly population also necessi-
tates the increase of medical and healthcare resources
[4]. In 2013, the cost of medical expenditure for the eld-
erly population was estimated to be 33 % of the total
Taiwan National Health Insurance program, which is al-
most three to four times than that of the non-elderly in
terms of the average cost per person [4].
Osteomyelitis is a common musculoskeletal infectious
disease in the elderly, second only to skin and soft tissue
infection [5]. The elderly are predisposed to osteomyelitis
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because of the immunocompromised nature of aging [6]
and comorbidities such as diabetes mellitus (DM), periph-
eral vascular disease, pressure ulcers, and surgical inter-
ventions [5, 7]. Osteomyelitis can be divided into three
subgroups according to the acuteness of the infectious
process: acute, subacute, and chronic osteomyelitis (CO)
[5]. Osteomyelitis in the elderly is most often caused by
pyogenic organisms, followed by Mycobacterium tuber-
culosis [5]. Acute osteomyelitis is usually caused by
hematogenous spread, and Staphylococcus aureus is the
most common pathogen in this context [5, 8]. Antimicro-
bial therapy alone for 4–6 weeks is usually effective for
treating acute and subacute osteomyelitis [5, 9]. CO may be
caused by S. aureus or Gram-negative organisms such as
Bacteroides fragilis [5, 9]. Because of the poor blood supply
to the infected bone, CO usually requires not only antibiotic
therapy but also adequate surgical debridement [5, 6, 9].
Other adjuvant therapies such as antibiotics, hyperbaric
oxygen, nutritional supplementation, advice on smoking
cessation, tight blood glucose control, arterial bypass sur-
gery, and discontinuation or alteration of medications are
recommended according to individual conditions [6]. Des-
pite the treatments, the persistence of CO is not uncom-
mon [5], which results in chronic disability, impairment of
the quality of life, and even an increased risk of long-term
mortality. Several epidemiological studies have reported
that CO increases the risk of subsequent coronary heart
disease [10], stroke [11], DM [12], renal disease [13], and
depression [14]. However, the long-term mortality risk of
CO in the elderly has not yet been clarified. Therefore, we
designed a retrospective nationwide population-based co-
hort study to delineate this issue. We hypothesized that
long-term mortality increased in the elderly with CO.
Methods
Data sources
Taiwan National Health Insurance program was a single-
payer program launched on March 1, 1995. Nearly 100 %
of Taiwan’s 23.75 million individuals, including foreigners,
were enrolled in the program [15]. This study was based
on the Longitudinal Health Insurance Database 2000
(LHID2000), which contains all the original claim data of
200,000 individuals randomly sampled from the 2000
Registry for Beneficiaries (ID) of the National Health In-
surance Research Database (NHIRD) (Fig. 1) [16]. The
NHIRD maintains the registration data of every individual
who was a beneficiary of the National Health Insurance
program during 1996–2000 [16]. There was no significant
difference in gender distribution between the patients in
the LHID2000 and the original NHIRD [16].
Study design, participants, and definitions
Initially, elderly patients (aged ≥ 65 years) who had CO
(ICD-9 code: 730.1) before 1999 were excluded (Fig. 1).
Then, the elderly patients with CO and those without
CO between January 1, 1999, and December 31, 2010,
were selected as the study cohort and the comparison
cohort, respectively, matched at a ratio of 1:10 by age
and gender. We categorized the study population on the
basis of their ages into three subgroups: young elderly
(65–74 years), moderately elderly (75–84 years), and old
elderly (≥85 years) for stratification analysis. CO is usu-
ally defined as osteomyelitis with a duration of more
than 6 weeks or as recurrent or non-curable osteomye-
litis [5]. The comorbidities that affect mortality were also
included in the study and defined as follows: DM (ICD-9
code 250), hypertension (HTN) (ICD-9 code 401–405),
renal disease (ICD-9 codes 582, 583, 585, 586, 588),
stroke (ICD-9 codes 430–438), congestive heart failure
(CHF) (ICD-9 code 428), liver disease (ICD-9 codes
5712, 5714, 5715, 5716, 4560–4562, 5722–5728), cancer
(ICD-9 codes 140–208), and chronic obstructive pul-
monary disease (COPD) (ICD-9 codes 490–496, 500–
505, 5064). Monthly income was also included as it is a
Fig. 1 Flowchart of the study. LHID, Longitudinal Health Insurance
Database; NHIRD, National Health Insurance Research Database; CO,
chronic osteomyelitis; IRR, incidence rate ratio
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potential confounding factor. Mortality risk between the
two cohorts was compared by following up until 2011. In-
dependent predictors of mortality were also investigated.
Ethic statements
This study was designed according to the Declaration of
Helsinki and approved by the Institutional Review Board
at Chi-Mei Medical Center. Informed consent was
waived because the LHID2000 used in this study con-
sists of unidentifiable and secondary data released to the
public for research purposes [16]. The rights and welfare
of the patients were not affected by the waiver.
Statistical analysis
Age, gender, comorbidities, and monthly income between
the two study cohorts were compared using Pearson χ2
tests for categorical variables and independent t test for
continuous variables. Mortality risk was compared by esti-
mating the incidence rate ratio (IRR) with conditional
Poisson regression. Kaplan–Meier analysis was used to
calculate the cumulative survival rate between the two co-
horts. Cox proportional hazard regression analysis was
used to investigate the independent predictors of mortality
after adjusting for age, gender, DM, HTN, renal disease,
stroke, CHF, liver disease, cancer, COPD, and monthly in-
come. SAS 9.3.1 for Windows (SAS Institute, Cary, NC,
USA) was used for all statistical analyses. Significance was
set at P < 0.05 (two-tailed).
Results
There was no significant difference in age and gender
between the two matched cohorts (Table 1). The mean
ages of patients with CO and those without CO were
74.89 ± 6.45 and 74.87 ± 6.43 years, respectively. Young
elderly (65–74 years) comprised the majority (~55 %)
followed by the moderately elderly (75–84 years)
(~37 %) in each cohort. There were more male patients
with CO than female patients (52 % vs. 48 %). Patients
with CO had significantly more number of comorbidities
such as DM, HTN, renal disease, stroke, CHF, cancer,
and COPD than patients without CO (all p < 0.05).
There was no significant difference in the monthly in-
come between the two cohorts.
After the 13-year follow-up period until 2011, patients
with CO showed a significantly higher mortality risk
than patients without CO [IRR: 2.29; 95 % confidence
interval (CI): 2.01–2.59] (Table 2). Stratification analysis
of age showed the highest mortality risk of CO in the
old elderly (≥85 years) (IRR: 3.27; 95 % CI: 2.22–4.82).
Male patients with CO had a higher mortality risk than
their female counterparts (IRR: 2.7 vs. 1.77). Subgroup
analyses of comorbidities such as DM, HTN, renal dis-
ease, stroke, cancer, and COPD also showed a higher
risk of mortality in the patients with CO than those
without CO. Stratification analysis of the follow-up
period data revealed the highest mortality risk in the first
month (IRR: 5.01; 95 % CI: 2.02–12.42), and the risk was
persistently higher throughout the follow-up period,
even after 6 years (IRR: 1.53; 95 % CI: 1.13–2.06), among
the patients with CO compared with those without CO.
The Kaplan–Meier survival analysis also showed that pa-
tients with CO had a significantly lower survival rate
than patients without CO (p < 0.0001) (Fig. 2).
Cox proportional hazard regression analysis showed
that CO was an independent predictor of mortality after
adjusting for age, gender, comorbidities, and monthly in-
come [adjusted hazard ratio (AHR): 1.89; 95 % CI: 1.66–
2.15] (Table 3). In addition, advanced age, male gender,
and all of the comorbidities included in this study were
independent predictors of mortality.
Discussion
This cohort study demonstrated that CO significantly in-
creased the risk of long-term mortality in the elderly pa-
tients during the 13-year follow-up period. The effect
was highest in the first month, which persisted even after
Table 1 Demographic characteristics and comorbidities of






(N = 965) (N = 9,650)
Age (years) 74.89 ± 6.45 74.87 ± 6.43 0.9213
65–74 531 (55.03) 5,322 (55.15) 0.9913
75–84 360 (37.31) 3,599 (37.30)
≥85 74 (7.67) 729 (7.55)
Gender
Male 502 (52.02) 5,020 (52.02) >0.999
Female 463 (47.98) 4,630 (47.98)
Comorbidity
DM 291 (30.16) 1,502 (15.56) <0.0001
HTN 438 (45.39) 3,369 (34.91) <0.0001
Renal disease 57 (5.91) 254 (2.63) <0.0001
Stroke 120 (12.44) 798 (8.27) <0.0001
CHF 49 (5.08) 238 (2.47) <0.0001
Liver disease 43 (4.46) 345 (3.58) 0.1645
Cancer 59 (6.11) 364 (3.77) 0.0004
COPD 133 (13.78) 847 (8.78) <0.0001
Monthly income
<NT$ 15,840 619 (64.15) 6,252 (64.79) 0.3735
NT$ 15,840–25,000 333 (34.51) 3,213 (33.30)
>NT$ 25,000 13 (1.35) 185 (1.92)
Data are N (%) or mean ± standard deviation
CO chronic osteomyelitis, DM diabetes mellitus, HTN hypertension, CHF
congestive heart failure, COPD chronic obstructive pulmonary disease, NT$
New Taiwan Dollars
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6 years, and the impact of CO was directly proportional to
the age of the patients. Male patients had a higher mortal-
ity risk than female patients if they had CO. In addition to
CO, comorbidities such as DM, HTN, renal disease,
stroke, CHF, liver disease, cancer, and COPD were also in-
dependent predictors of mortality.
The increased long-term mortality in the elderly due to
CO could probably be attributed to infection, chronic in-
flammatory reaction, and CO-related chronic complica-
tions such as impaired limb function and psychological
status. CO can occur as a result of microorganisms origin-
ating from the hematogenous route, spread of infection to
the bone from the adjacent soft tissues and joints, or post-
trauma or post-surgery infection [5, 17]. S. aureus is the
commonest causative organism of hematogenous CO, al-
though multiple organisms are usually isolated in cases
where CO results from direct inoculation or through
contiguous spread [5, 18]. Underlying the pathological
processes of infection are inflammation, suppuration, ne-
crosis, exudation, vascular congestion and intraosseous
HTN, intravascular thrombosis with occlusion of blood
flow, and reactive new bone formation [19]. Because of
the presence of sequestrum (dead bone) in CO, it is
always very difficult to eradicate the infection completely
[5, 7, 19]. The mainstay treatments for CO are surgical de-
bridement, management of ensuing dead space, adjunctive
antibiotic therapy, reconstruction of soft tissue defects,
and hyperbaric oxygen therapy [5, 7, 19]. However, the
elderly patients are always too frail to receive complete
surgical debridement with adjunctive therapy in the real
situation, which results in the non-curable nature of the
disease and a vicious cycle of the general conditions.
Chronic inflammatory reaction is a risk factor for car-
diovascular disease and even death [20, 21]. Inflammation
Table 2 Comparison of mortality risk for elderly patients with and without CO
Characteristics Elderly patients with CO Elderly patients without CO IRR (95 % CI) p-value
N Death PYa Rateb N Death PYa Rateb
All 965 289 5131.3 56.32 9650 1456 59034.95 24.66 2.29 (2.01–2.59) <0.0001
Age (years)
65–74 531 128 3097.15 41.33 5322 643 34007.74 18.91 2.19 (1.81–2.65) <0.0001
75–84 360 129 1720.28 74.99 3599 688 21018.46 32.73 2.29 (1.9–2.76) <0.0001
≥85 74 32 313.87 101.95 729 125 4008.75 31.18 3.27 (2.22–4.82) <0.0001
Gender
Male 502 194 2611.37 74.29 5020 877 31878.11 27.51 2.7 (2.31–3.16) <0.0001
Female 463 95 2519.93 37.7 4630 579 27156.85 21.32 1.77 (1.42–2.2) <0.0001
Comorbidity
DM 291 113 1446.51 78.12 1502 341 8489.47 40.17 1.94 (1.57–2.41) <0.0001
HTN 438 134 2286.75 58.6 3369 621 19093.71 32.52 1.8 (1.49–2.17) <0.0001
Renal disease 57 28 218.35 128.23 254 78 1308.83 59.6 2.18 (1.41–3.36) 0.0004
Stroke 120 52 543.46 95.68 798 215 4255.75 50.52 1.89 (1.4–2.56) <0.0001
CHF 49 19 208.15 91.28 238 78 1207.95 64.57 1.41 (0.86–2.33) 0.176
Liver disease 43 15 235.48 63.7 345 85 2011.18 42.26 1.51 (0.87–2.61) 0.143
Cancer 59 30 211.4 141.91 364 104 1670.29 62.26 2.28 (1.52–3.42) <0.0001
COPD 133 52 644.82 80.64 847 256 4937.64 51.85 1.56 (1.15–2.1) 0.0037
Follow-up period
0–1 month 965 7 80.15 87.34 9650 15 803.5 18.67 5.01 (2.02–12.42) 0.0005
1–6 months 958 43 389.54 110.39 9635 86 3997.24 21.52 5.13 (3.56–7.4) <0.0001
6–12 months 915 37 448.48 82.5 9549 127 4742.7 26.78 3.08 (2.14–4.44) <0.0001
1–2 years 878 51 815.21 62.56 9422 188 8964.55 20.97 2.98 (2.19–4.07) <0.0001
2–4 years 757 64 1305.36 49.03 8489 328 14932.6 21.97 2.23 (1.71–2.92) <0.0001
4–6 years 552 39 917.42 42.51 6389 320 10909.76 29.33 1.45 (1.04–2.03) 0.0274
>6 years 380 48 1175.14 40.85 4604 392 14684.61 26.69 1.53 (1.13–2.06) 0.0054
aPY person-years
bRate: per 1000 person-years
Data are N (%) or mean ± standard deviation
CO chronic osteomyelitis, IRR incidence rate ratio, CI confidence interval, DM diabetes mellitus, HTN hypertension, CHF congestive heart failure, COPD chronic
obstructive pulmonary disease
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triggers the production of proinflammatory cytokines in
the arterial wall [22]. Primary cytokines such as tumor ne-
crosis factor-α and interleukin-1 mediate the attraction
and migration of inflammatory cells into the vascular tis-
sue [22]. They also induce the “messenger” cytokines,
which are released into the systemic circulation, causing
the liver to increase the production of acute phase reac-
tants such as C-reactive protein and serum amyloid A,
which amplify the inflammatory and procoagulant re-
sponses [22–24]. Other risk factors including concomitant
DM, HTN, and smoking also add to the inflammation
[21]. Finally, all these processes lead to vascular athero-
sclerosis and cardiovascular events.
The high number of comorbidities suggesting a poor
underlying condition renders the elderly particularly vul-
nerable to CO, which in turns causes more chronic com-
plications including limb deformities, limb length
inequality, impaired limb function, pathological frac-
tures, malignant transformation, compartment syndrome
and Volkmann contracture, coronary heart disease [10],
stroke [11], DM [12], chronic renal failure [13], loss of
self-esteem and depression [14], and secondary amyloid-
osis leading to nephrotic syndrome [19]. Our results
showed that elderly patients with chronic comorbidities
had higher mortality risk when they had CO. Further-
more, chronic comorbidities also predicted the subse-
quent mortality in the elderly. The extremity disability
caused by CO results in decreased daily activities and el-
evated risk of other chronic physical and psychological
disorders [14], which also may increase the risk of mor-
tality when combining with previous comorbidities. This
is a vicious circle suggesting that both prevention of CO
and control of comorbidities are very important manage-
ment strategies for the elderly with CO.
There are some limitations to this study. First, there was
no detailed information regarding the treatment strategies
(e.g., surgery, antibiotics, hyperbaric oxygen, etc.), labora-
tory data, lifestyle, and personal health factors including
smoking and obesity, which may be confounding factors.
Second, we did not classify CO into subgroups based on
the affected area (i.e., infection site) such as vertebrae, hip,
sacrum, sternum, or mandible and the induced mecha-
nisms such as traumatic, hematogenous, diabetic, post-
surgery or pressure ulcer, which may have a different
prognosis. Nevertheless, as this study was designed to in-
vestigate the long-term effects of CO in the elderly, sub-
group analysis was beyond the primary goal. Third,
potential information biases due to misclassification by
the ICD-9-CM diagnosis codes in NHIRD may exist; how-
ever, this misclassification is likely nondifferential. Because
nearly 100 % Taiwan’s 23.75 million individuals were
Fig. 2 Kaplan–Meier survival analysis of patients with and without
CO. CO, chronic osteomyelitis
Table 3 Cox proportional hazard regression analysis for
mortality risk in the elderly patients









75–84 1.74 (1.57–1.91)* 1.69 (1.53–1.87)*
≥85 1.76 (1.49–2.10)* 2.02 (1.70–2.41)*
Gender
Male 1.36 (1.24–1.50)* 1.34 (1.22–1.48)*
Female 1.000 1.000
Comorbidity
DM 1.92 (1.73–2.14)* 1.71 (1.53–1.92)*
HTN 1.53 (1.39–1.68)* 1.16 (1.05–1.29)*
Renal disease 2.66 (2.19–3.24)* 2.03 (1.66–2.47)*
Stroke 2.24 (1.97–2.56)* 1.82 (1.59–2.08)*
CHF 2.61 (2.13–3.20)* 1.86 (1.51–2.29)*
Liver disease 1.68 (1.37–2.05)* 1.47 (1.201.81)*
Cancer 2.77 (2.32–3.31)* 2.41 (2.02–2.88)*
COPD 2.25 (1.99–2.54)* 1.77 (1.56–2.01)*
Monthly income
<NT$ 15,840 1.71 (1.08–2.68)* 1.50 (0.95–2.36)
NT$ 15,840–25,000 1.34 (0.85–2.12) 1.27 (0.8–2.02)
>NT$ 25,000 1.000 1.000
*p-value < 0.05
CI confidence interval, DM diabetes mellitus, HTN hypertension, CHF
congestive heart failure, COPD chronic obstructive pulmonary disease, NT$
New Taiwan Dollars
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enrolled into NHIRD, we thought the selection bias is very
small. Fourth, we did not have the data of direct causes of
death in this study. Further studies are warranted to ad-
dress these issues. For example, a prospective well-
designed study with detailed data including mechanism of
infection, infection site, treatment strategies, and more
important measures for physical as well as psychological
assessment such as SF-36 (Short Form 36 Health Surveys),
would better evaluate the effect of CO on mortality in the
elder patients.
Conclusions
This is the first nationwide population-based cohort
study delineating that CO increased the long-term mor-
tality in the elderly, particularly in the males and those
with an advanced age. The effect was most significant in
the first month and persisted even after 6 years. In
addition to CO, chronic underlying comorbidities also
predict the mortality. Early prevention and treatment of
CO and concomitant control of comorbidities are the
suggested management strategies for the elderly with
CO.
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